お知らせ • Mar 06
Mithra Pharmaceuticals SA Announces CEO Changes Mithra Pharmaceuticals SA announced the termination of the management agreement with David Horn Solomon as CEO and his replacement by Christophe Maréchal and Xavier Paoli as co-CEOs. As announced, Mithra will commence a monetization process involving the sale of various selected assets of Mithra and/or the business as a whole (the "Monetization Process"). Concurrent therewith, the board of directors decided that a change in Mithra's management was needed. Therefore, Mr. Solomon’s1management agreement was terminated with immediate effect. To lead Mithra from now on, the board of directors has decided to appoint Christophe Maréchal and Xavier Paoli as co-CEOs pending the implementation of the Monetization Process. Christophe Maréchal has been Chief Financial Officer (CFO) at Mithra since the beginning of 2017. With more than 20 years of experience in international finance in the industrial, telecommunications, manufacturing, and banking industries, he has strong skills in operational, financial, and commercial strategy. Xavier Paoli has been Chief Operating Officer (COO) at Mithra since September 2023. Xavier Paoli has a 20-year international career in the biotech and biopharmaceutical industry, with deep experience and knowledge of the full biotech value chain from fundraising to commercialization. Already involved in the day-to-day management of Mithra and in all its strategic and operational decisions, with the support of the board of directors and the entire management team, Christophe Maréchal2 and Xavier Paoli have all the expertise required to take over as co-CEOs of Mithra. お知らせ • May 29
Mithra Appoints Christian Homsy as Chairman Mithra announced the appointment of leading life sciences executive Dr. Christian Homsy as Chairman of the Board of Directors. The Board of Directors also appointed Inge Beernaert as President of the Compensation and Nomination Committee and Gaudeto, represented by Jacques Galloy as President of the Audit Committee. Christian Homsy, who recently joined the Board as an Independent Director of Mithra, has more than 30 years’ experience in the life sciences industry, most recently as founder and interim Chief Executive Officer and Board Member of Capstan Therapeutics. He was also founder, Chief Executive Officer and Board Member of Celyad SA and spent the first part of his career in senior roles at Guidant Corporation, now part of Boston Scientific and Abbott. Christian gained his Medical Doctorate at the University of Louvain, Belgium and his MBA at IMD Business School, Lausanne, Switzerland. お知らせ • May 26
Mithra Approves Board Appointments Mithra at its Annual General Meeting, held on May 25, 2023, approved the appointment of new directors for a two-year mandate as follows: Ribono SRL, Mr. Sidney Bens (Independent Director) Sidney is a seasoned financial executive, with over 35 years’ experience. He spent most of his career at Atenor, where he served as Chief Financial Officer. Prior to this he worked in banking, as Senior Corporate Banker at Paribas Bank Belgium (now Belfius) and in Retail and SMC banking at BBL (now ING). Sidney holds a Masters degree in Finance, Accounting and Trade from Lucien Cooremans Institute, Belgium and a Postgraduate in Finance from KU Leuven, Belgium. Mrs. Igne Beernaert (Independent Director) Igne is an experienced financial services professional, specializing in audit, corporate finance, internal controls, tax, management and M&A. She is the founder of Bedrijfsrevisor Beernaert, where she served as company auditor for the last 27 years. Prior to this, she founded bb3 Revisoren, another financial advisory firm. Igne holds a Masters degree in Applied Economics from KU Leuven, Belgium and a postgraduate degree in liability and insurance law from the University of Antwerp. Life Science Strategy Consulting SRL, Mr. Christian Homsy (Independent Director) Christian is a leading life sciences executive with over 30 years’ industry experience. Most recently he founded and served as interim Chief Executive Officer and Board Member of biotechnology company Capstan Therapeutics. He was also founder, Chief Executive Officer and Board Member of Celyad SA for 15 years. He spent a large part of his career at Guidant Corporation (part of Boston Scientific and Abbott Labs) in a number of senior roles. Christian gained his Medical Doctorate at the University of Louvain, Belgium and his MBA at IMD Business School, Lausanne, Switzerland. Gaudeto SRL, Mr. Jacques Galloy (Independent Director) Jacques has over 25 years of business leadership experience including private and public equity capital markets, focusing on digital imaging, medical technology, digital media and digital transition. He is currently the founder and managing partner of Guadeto SPRL. He is a current investor in 7 companies, entrepreneur in 5 businesses and charities, and has over 10 board mandates. He also has 12 years’ experience as Board member and CFO of EVS Broadcast Equipment SA. Jacques holds a Masters in Commercial Engineering from Ulg-HEC Liège, Belgium. Board Change • Nov 16
Less than half of directors are independent There are 7 new directors who have joined the board in the last 3 years. Of these new board members, 4 were independent directors. The company's board is composed of: 7 new directors. 2 experienced directors. No highly experienced directors. 4 independent directors (5 non-independent directors). President of the Scientific Advisory Board & Executive Director Jean-Michel Foidart is the most experienced director on the board, commencing their role in 2016. Independent Vice Chairman Erik Van Eynden was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Board Change • Apr 27
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Independent Chairman Ajit Shetty was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.